Rojalin Nayak – The Molecular Maverick Revolutionizing Cancer Research with Innovative Drug Discoveries

**Rojalin Nayak**

**CONTACT**
Habitat Irenic, Choodasandra Rd,
Choodasandra, Bengaluru, Karnataka
560099

**PERSONAL INFO**
National Institute of Technology, Rourkela
2018-2024 [hidden]
Khallikote University
2015-2017 Master of Science in Biotechnology

**EDUCATION**
– [hidden] Topic: Study the impact of UV-C irradiation on the solubility of Osborne protein fractions in wheat flour
– [hidden] Biotechnology: Khallikote University, 2015-2017

**SKILLS**
– Python
– Docking
– MD Simulation
– Statistical Analysis
– Gel Electrophoresis
– DNA, RNA Extraction
– PCR, q-RT PCR
– SDS PAGE
– Cell Culture
– Bacterial Culture
– Flow Cytometry
– Molecular Experiments

**ABOUT ME**
I am a dedicated researcher focused on advancing cancer therapeutics through molecular biology and computational methodologies. My expertise lies in repurposed drug prediction and personalized medicine. I aim to decipher molecular mechanisms, identify novel therapeutic strategies, and discover new drugs. Through molecular approaches, I am passionate about demonstrating the potential of these treatments and developing effective therapies for various diseases.

**PROJECTS**
– Identification of new drug(s) for treating endometriosis-associated infertility by drug repurposing using signature microRNAs
– Genome-wide profiling of small ncRNA and investigating their role in Glioblastoma
– Prediction of repurposed drugs to improve the Temozolomide treatment in Glioblastoma

**PUBLICATIONS**
1. Nayak R, Chattopadhyay T, Gupta P, Mallick B. Integrative analysis of small non-coding RNAs predicts a piRNA/miRNA-CCND1/BRAF/HRH1/ATXN3 regulatory circuit that drives oncogenesis in glioblastoma. Mol Omics. 2023;19(3):252-61
2. Nayak R, Mallick B. LncRNA-associated competing endogenous RNA network analysis uncovered key lncRNAs involved in temozolomide resistance and tumor recurrence of glioblastoma. J Mol Recognit. 2023;36(12):e3060
3. Chattopadhyay T, Gupta P, Nayak R, Mallick B. Genome-wide profiling of dysregulated piRNAs and their target genes implicated in oncogenicity of tongue squamous cell carcinoma. Gene. 2023;849:146919
4. Nayak R, Chattopadhyay T, Mallick B. Identification of potential repurposed drugs for treating endometriosis-associated infertility among women. Chem Biol Interact. 2022;365:110110
5. Roy J, Anand K, Mohapatra S, Nayak R, Chattopadhyay T, Mallick B. Single nucleotide polymorphisms in piRNA-pathway genes: an insight into genetic determinants of human diseases. Mol Genet Genomics. 2020;295(1):1-12
6. Nayak R, Mallick B. BMS345541 is predicted as a repurposed drug for the treatment of TMZ-resistant Glioblastoma using target gene expression and virtual drug screening. Intl J Biological Macromolecules. (under review)
7. Kumar A, Nayak R, Purohit S, Rao, P. Impact of UV-C irradiation on solubility of Osborne protein fractions in wheat flour. Food Hydrocolloids. 2021:110

**TOOLS**
– Swiss Dock
– Auto Dock
– Pymol
– Discovery Studio
– Cytoscape
– NAMD
– Galaxy Server
– MS Excel
– Powerpoint
– Prism
– Origin
– Power BI
– Image J

**Keywords:**
Cancer Therapeutics, Molecular Biology, Computational Methodologies, Repurposed Drug Prediction, Personalized Medicine, Molecular Mechanisms, Therapeutic Strategies, New Drug Discovery, Python, MD Simulation, Statistical Analysis, Gel Electrophoresis, DNA, RNA Extraction.

Cover Letter:

Dear Hiring Team,
I am writing to express my interest in the Genome Analyst position. With a strong background in molecular biology, computational methodologies, and extensive experience in statistical analysis and bioinformatics, I am excited about the opportunity to contribute to your team.
During my PhD at NIT Rourkela, I focused on predicting non-coding RNA and repurposed drugs in glioblastoma through in silico studies, utilizing molecular docking, molecular dynamics simulation, and advanced statistical analysis. My current role as a Research Associate-I at IISc has further honed my expertise in exploring RNA-protein interactions and the molecular mechanisms of disease progression, equipping me with the skills necessary for complex genomic data interpretation.
I am proficient in Python for data analysis, and my experience with tools such as Discovery Studio and PyMOL has allowed me to analyze biomolecular interactions at a detailed level. My background in cancer therapeutics and personalized medicine aligns with the role’s objectives, and I am eager to bring my interdisciplinary approach to your team.
I am enthusiastic about the opportunity to contribute my skills and collaborate with experts to advance genomic research. Thank you for considering my application. I look forward to discussing how I can contribute to your team.
Sincerely,
Rojalin Nayak